Loading company…
Tafalgie Therapeutics develops peptide medicines for acute and chronic pain.
Tafalgie Therapeutics researches analgesic peptides that target TAFA4, a protein involved in pain signaling. Its pipeline includes candidates for post-operative pain, rare diseases, and acute and chronic pain, with programs ranging from preclinical research to Phase 2 trials. Founded in 2020 by Aziz MOQRICH, Stéphane GAILLARD, Eric SCHETTINI, and Laurent LABATUT, the company is based in France. In September 2025, it raised EUR 18.5 million in Series A and venture debt funding from Bpifrance and the European Innovation Council.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in